A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577

BACKGROUND: Results of CheckMate 577 show an improved disease-free survival for patients with resected esophageal or gastroesophageal junction cancer treated with adjuvant nivolumab compared with placebo (22.4 versus 11.0 months). Population-based data can provide insights in outcomes from clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Pape, Marieke, Vissers, Pauline A.J., Beerepoot, Laurens V., van Berge Henegouwen, Mark I., Lagarde, Sjoerd M., Mook, Stella, Moehler, Markus, van Laarhoven, Hanneke W.M., Verhoeven, Rob H.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883292/
https://www.ncbi.nlm.nih.gov/pubmed/35237351
http://dx.doi.org/10.1177/17588359221075495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883292/
https://www.ncbi.nlm.nih.gov/pubmed/35237351
http://dx.doi.org/10.1177/17588359221075495

Ejemplares similares